Verified1

Stanford Cancer Institute
Stanford MEDICINE

Version Date:
September 1, 2023

Stanford Cancer Institute

Cancer Cell Therapy

Non-Hodgkin Lymphoma

- Relapsed or Refractory → **CCT5084** Phase I/II Dose-Exploration & Expansion Study Evaluating Safety & Efficacy of Multiplex Base-Edited Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed / Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
  PI: Weng
  Sponsor: Beam Therapeutics Inc.
- T-Cell Lymphoblastic Lymphoma (T-LL)
- ≥ 18 Yrs
  - **Diffused Large B-Cell Lymphoma**
    - Relapsed or refractory disease after CD19-directed therapy
      - **CCT5089** Phase II CRG-022 a CD22- Directed Autologous Chimeric Antigen Receptor (CAR) T-Cell Therapyin Relapsed/ Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-Cell Therapy
        PI: Frank
        Sponsor: CARGO Therapeutics, Inc.
        Priority: 1st
      - **CCT5062** Phase I/II bbT369 Dual Targeting CAR T-Cell Drug Product w/ Gene Edit in Relapsed and/or Refractory B-Cell NHL
        PI: Miklos
        Sponsor: 2seventy bio, Inc.
        Priority: 2nd
      - **CCT5041** Phase I Anti-CD70 CRISPR-Cas9-Engineered T-Cells (CTX130) in Relapsed/ Refractory T/B-Cell Malignancies
        PI: Weng
        Sponsor: CRISPR
    - Relapsed or refractory disease third-line
      - **CCT5016** Managed Access Program (MAP) CTL019 in ALL or DLBCL
        PI: Miklos
        Sponsor: Novartis
      - **CCT5001** Phase I CD19/CD22 Chimeric Antigen Receptor (CAR) T-Cells in Recurrent/ Refractory B-Cell Malignancies ❖
        PI: Miklos
        Sponsor: Stanford University
        Priority: 1st
    - First Line
      - **CCT5072** Adaptive Phase III Randomized Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel vs Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma
        PI: Miklos
        Sponsor: Kite Pharma, Inc.
    - 2nd Line Relapsed and/or Refractory Disease
      - **CCT5068** Phase Ib Open Label Study to Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma after Standard of Care Axi-Cel
        PI: Dahiya
        Sponsor: Stanford University
    - Will replace CCT5024 after it opens
      - **CCT5043** Phase I/II ALLO-501A Anti-CD19 Allogenic Car T-Cell Tx in Relapsed /Refractory Large B-Cell Lymphoma
        PI: Miklos
        Sponsor: Allogene
    - Relapsed/ Refractory After SOC axi-cel liso-cel tisa-cel
      - **CCT5087** Phase II/III Randomized Double Blind Placebo-Controlled Multicenter Study of NKTR-255 vs Placebo Following CD19-Directed CAR-T Cell Therapy in Relapsed/ Refractory Large B-Cell Lymphoma
        PI: Dahiya
        Sponsor: Nektar Therapeutics
    - End of Line
- CLL
  - End of Line
  - Relapsed or Refractory Disease >= Two Prior Lines
    - **CCT5067** Phase I Study of FT819 in B-cell Malignancies
      PI: Miklos
      Sponsor: Fate Therapeutics Inc.
      - >= 2 Prior Lines or After Auto-ASCT
        - **CCT5082** Phase I Study Evaluating SC291 Hypoimmune Allogeneic CD19-Directed CAR T Cell Therapy in Relapsed and/or Refractory B-Cell Malignancies (ARDENT)
          PI: Dahiya
          Sponsor: Sana Biotechnology, Inc.
- Folicular Lymphoma
  - Relapsed or Refractory Disease >= Two Prior Lines
    - **CCT5066** Phase III Randomized Axicabtagene Ciloleucel Versus Standard of Care Therapy in Relapsed or Refractory Follicular Lymphoma
      PI: Frank
      Sponsor: Kite Pharma, Inc.
- WM
- HCL
  - Relapsed or Refractory >= Two Prior Lines
- BL
- RT
  - Relapsed or Refractory after One Line
  - **CCT5074** Phase II, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexu-cabtagene Autoleucel in Adults with Rare B-Cell Malignancies (ZUMA-25)
    .
    PI: Dahiya
    Sponsor: Kite Pharma, Inc.

KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link — Trial Posting
- Enrollment on Hold
- Extension Study
- ❖ Immunotherapy

Please mark up a copy using black ink and email changes t